Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma
<p>Abstract</p> <p>Background</p> <p>Although numerous chemotherapeutic agents have been tested, the role of systemic chemotherapy for hepatocellular carcinoma (HCC) has not been clarified. New therapeutic strategies are thus needed to improve outcomes, and we designed...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2006-01-01
|
| Series: | BMC Cancer |
| Online Access: | http://www.biomedcentral.com/1471-2407/6/3 |
| _version_ | 1828272230161711104 |
|---|---|
| author | Bang Soo-Mee Lee Jeong Park Yeon Kim Ju Kim Sun Kwon Oh Kwon So Han Sang Lee Yuna Park Se Cho Eun Shin Dong Lee Jae |
| author_facet | Bang Soo-Mee Lee Jeong Park Yeon Kim Ju Kim Sun Kwon Oh Kwon So Han Sang Lee Yuna Park Se Cho Eun Shin Dong Lee Jae |
| author_sort | Bang Soo-Mee |
| collection | DOAJ |
| description | <p>Abstract</p> <p>Background</p> <p>Although numerous chemotherapeutic agents have been tested, the role of systemic chemotherapy for hepatocellular carcinoma (HCC) has not been clarified. New therapeutic strategies are thus needed to improve outcomes, and we designed this study with new effective drug combination.</p> <p>Methods</p> <p>Twenty-nine patients with histologically-confirmed, metastatic HCC received a combination chemotherapy with doxorubicin 60 mg/m<sup>2 </sup>and cisplatin 60 mg/m<sup>2 </sup>on day 1, plus capecitabine 2000 mg/m<sup>2</sup>/day as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest.</p> <p>Results</p> <p>The median age was 49 years (range, 32–64) and 19 patients were hepatitis B virus seropositive. Child-Pugh class was A in all patients and 4 had Zubrod performance status of 2. The objective response rate was 24% (95% CI 9–40) with 6 stable diseases. The chemotherapy was generally well tolerated despite one treatment-related death.</p> <p>Conclusion</p> <p>Combination chemotherapy with doxorubicin, cisplatin and capecitabine produced modest antitumor activity with tolerable adverse effects in patients with metastatic HCC.</p> |
| first_indexed | 2024-04-13T06:03:42Z |
| format | Article |
| id | doaj.art-db9a35de81414c74b51cb4c32f7626e4 |
| institution | Directory Open Access Journal |
| issn | 1471-2407 |
| language | English |
| last_indexed | 2024-04-13T06:03:42Z |
| publishDate | 2006-01-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Cancer |
| spelling | doaj.art-db9a35de81414c74b51cb4c32f7626e42022-12-22T02:59:21ZengBMCBMC Cancer1471-24072006-01-0161310.1186/1471-2407-6-3Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinomaBang Soo-MeeLee JeongPark YeonKim JuKim SunKwon OhKwon SoHan SangLee YunaPark SeCho EunShin DongLee Jae<p>Abstract</p> <p>Background</p> <p>Although numerous chemotherapeutic agents have been tested, the role of systemic chemotherapy for hepatocellular carcinoma (HCC) has not been clarified. New therapeutic strategies are thus needed to improve outcomes, and we designed this study with new effective drug combination.</p> <p>Methods</p> <p>Twenty-nine patients with histologically-confirmed, metastatic HCC received a combination chemotherapy with doxorubicin 60 mg/m<sup>2 </sup>and cisplatin 60 mg/m<sup>2 </sup>on day 1, plus capecitabine 2000 mg/m<sup>2</sup>/day as an intermittent regimen of 2 weeks of treatment followed by a 1-week rest.</p> <p>Results</p> <p>The median age was 49 years (range, 32–64) and 19 patients were hepatitis B virus seropositive. Child-Pugh class was A in all patients and 4 had Zubrod performance status of 2. The objective response rate was 24% (95% CI 9–40) with 6 stable diseases. The chemotherapy was generally well tolerated despite one treatment-related death.</p> <p>Conclusion</p> <p>Combination chemotherapy with doxorubicin, cisplatin and capecitabine produced modest antitumor activity with tolerable adverse effects in patients with metastatic HCC.</p>http://www.biomedcentral.com/1471-2407/6/3 |
| spellingShingle | Bang Soo-Mee Lee Jeong Park Yeon Kim Ju Kim Sun Kwon Oh Kwon So Han Sang Lee Yuna Park Se Cho Eun Shin Dong Lee Jae Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma BMC Cancer |
| title | Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma |
| title_full | Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma |
| title_fullStr | Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma |
| title_full_unstemmed | Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma |
| title_short | Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma |
| title_sort | systemic chemotherapy with doxorubicin cisplatin and capecitabine for metastatic hepatocellular carcinoma |
| url | http://www.biomedcentral.com/1471-2407/6/3 |
| work_keys_str_mv | AT bangsoomee systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT leejeong systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT parkyeon systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT kimju systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT kimsun systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT kwonoh systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT kwonso systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT hansang systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT leeyuna systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT parkse systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT choeun systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT shindong systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma AT leejae systemicchemotherapywithdoxorubicincisplatinandcapecitabineformetastatichepatocellularcarcinoma |